Qualification
- MB BCh., Faculty of Medicine, Egypt.
- MSc. Clinical Oncology, Egypt.
- Doctorate in Medicine MD. Oncology, Egypt.
- DMRT (Diploma in Medical Oncology and Radiation Therapy), Faculty of Clinical Oncology, The Royal College of Radiologists (RCR), London - UK.
- Certified by the European Society for Medical Oncology (ESMO) Geneva, Switzerland.
- Re- Accreditation by the European Society for Medical Oncology (ESMO)
- Re- Accreditation by the European Society for Medical Oncology (ESMO)
Prof. Medhat Faris is a distinguished Medical Oncologist Consultant with extensive experience in Medical Oncology. He earned his MBBCh, MSc, and MD in Clinical Oncology from Egypt, and holds a Diploma in oncology from Faculty of clinical Oncology, The Royal College of Radiologists in London. Certified by the European Society for Medical Oncology (ESMO).
With a robust background in clinical trials and research, Dr. Faris specializes in treating various adult Solid Tumours. He is actively involved in international medical societies and has received accolades for his contributions to cancer research and early detection. His commitment extends to community education and awareness, making him a respected leader in oncology.
Professional Experience
- Consultant Medical Oncologist at Advanced care oncology centre, IMH from the m 2021 to 2024.
- Consultant/Medical Advisor, Watson Health for Oncology, IBM Middle East, Dubai, UAE 2018-2021
- Chairman of Adult Medical Oncology Department, King Fahad Specialist Hospital, Dammam, Saudi Arabia 2012-2018
- Vice Dean for Graduate Studies and Research, Cancer Institute, Egypt2010-2012
- Medical Director, Clinical Research & Medical Affairs, EMEA & Asia at Pharmaceutical Products Development (PPD), Cambridge, UK2008-2010
- Head of Medical Oncology and Senior Consultant, The Royal Hospital, Muscat, Sultanate of Oman 1998-2008
- Medical Oncologist, Addenbrooke’s Hospital, Cambridge University, UK 2000-2002
Expertise
- Management and Treatment Plans for Adult Solid Tumours including but not limited to:
- Early and advanced Breast cancer
- Lung cancer
- Colorectal & Stomach cancer
- Female genital system Tumours (Ovarian cancer, Cervix and Uterine)
- Male Genital system Tumours (Prostate cancer, Testicular cancer, Bladder cancer
- Renal cancer
- Head and neck cancer
- High-risk patients with breast cancer carrying BRCA1 and BRCA2 mutations
